Schedules of Doxorubicin, Cyclophosphamide, Paclitaxel in High-Risk Early-Stage Breast Cancer Compared
the Cancer Therapy Advisor take:
Adjusted weekly dosing for doxorubicin and cyclophosphamide as well as pacilataxel shows similar disease-free survival rates in patients with early-stage breast cancer, according to a recent study published in the Journal of Clinical Oncology.
Comparing continuous with once-every-two-weeks dosing of doxorubicin and cyclophoshamide, as well as once-a-week with six cycles once-every-two-weeks for pacilataxel, researchers found similar disease-free survival rates in any of these regimens in 3,250 patients.
While overall survival was significantly different in each of the four arms, with all treatments that were given once-every-two-weeks being associated with the highest overall survival, this distinction seemed confined only to patients with hormone receptor-negative/human epidermal growth factor receptor 2 (HER2)-negative tumors. The overall survival rate was similar in patients with hormone receptor-positive/HER2-negative or HER2-positive tumors.
Led by George Budd, MD, of the Cleveland Clinic, the study aimed to determine optimal dosage and scheduling of anthracycline and taxane as adjuvant therapy for early-stage breast cancer. They concluded that, upon subset analysis, once-every-two-weeks dosage may be best for patients with hormone receptor-negative/HER2-negative tumors.
Adjusted weekly dosing for doxorubicin and cyclophosphamide as well as pacilataxel shows similar disease-free survival rates.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Immunotherapy in Glioblastoma: Peaks and Pits
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Opinion: Understanding the FDA's Take on Cannabidiol
- OS and PFS End Points Not Met in Phase 3 Trial of Pembrolizumab in Advanced HCC
- No Benefit Observed With Osimertinib Plus Durvalumab in EGFR-Mutated NSCLC
- Evidence of the Role of Circulating Insulin in Renal Cell Carcinoma Risk
- Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
- American Society of Breast Surgeons Recommends Genetic Testing for All Patients With Breast Cancer